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Abstract
Background: The consequences of defective homologous recombination (HR) are not understood in sporadic ovarian
cancer, nor have the potential role of HR proteins other than BRCA1 and BRCA2 been clearly defined. However, it is clear
that defects in HR and other DNA repair pathways are important to the effectiveness of current therapies. We hypothesize
that a subset of sporadic ovarian carcinomas may harbor anomalies in HR pathways, and that a BRCAness profile (defects in
HR or other DNA repair pathways) could influence response rate and survival after treatment with platinum drugs. Clinical
availability of a BRCAness profile in patients and/or tumors should improve treatment outcomes.
Objective: To define the BRCAness profile of sporadic ovarian carcinoma and determine whether BRCA1, PARP, FANCD2,
PTEN, H2AX, ATM, and P53 protein expression correlates with response to treatment, disease recurrence, and recurrence-
free survival.
Materials and Methods: Protein microarray analysis of ovarian cancer tissue was used to determine protein expression
levels for defined DNA repair proteins. Correlation with clinical and pathologic parameters in 186 patients with advanced
stage III–IV and grade 3 ovarian cancer was analyzed using Chi square, Kaplan-Meier method, Cox proportional hazard
model, and cumulative incidence function.
Results: High PARP, FANCD2 and BRCA1 expressions were significantly correlated with each other; however, elevated p53
expression was associated only with high PARP and FANCD2. Of all patients, 9% recurred within the first year. Among early
recurring patients, 41% had high levels of PARP, FANCD2 and P53, compared to 19.5% of patients without early recurrence
(p=0.04). Women with high levels of PARP, FANCD2 and/or P53 had first year cumulative cancer incidence of 17%
compared with 7% for the other groups (P=0.03).
Conclusions: Patients with concomitantly high levels of PARP, FANCD2 and P53 protein expression are at increased risk of
early ovarian cancer recurrence and platinum resistance.
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Introduction
Ovarian cancer is the second most common gynecologic
malignancy and the most common cause of death among women
with a gynecologic cancer. About 21,000 ovarian cancer cases are
diagnosed annually, and about 14,000 deaths from ovarian cancer
occur each year [1]. Although significant improvements have been
made over the past several decades to extend median life span
after ovarian cancer diagnosis, less than 30% of patients can be
cured with optimal surgical cytoreduction and standard adjuvant
chemotherapy with a platinum-containing agent, and long term
survival has not improved [2].
Patients with mutations of BRCA1 or BRCA2, genes involved
in the repair of double-stranded DNA breaks by homologous
recombination (HR), have increased sensitivity to platinum
chemotherapy, thus improving their overall survival outcome
[3–5]. Additionally, cells with pre-existing defects in the HR
pathway (BRCA 1 or BRCA 2 mutation) can be targeted by a
second hit in the form of an inhibition of the base excision repair
(BER) pathway which leads to cell death. This concept of synthetic
lethality – the combination of two genetic alterations, which on
their own are non-lethal, but together result in a lethal phenotype
– led to interest in inhibitors of BER pathways. One such BER
inhibitor is the poly-ADP ribose polymerase (PARP) inhibitor,
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therapy-induced DNA injury [6–8]. While normal cells can repair
the damage and survive, the BRCA-deficient cells cannot activate
the HR system and therefore they die (6). PARP inhibitors have
demonstrated promising results in patients with BRCA1- or
BRCA2-positive ovarian cancer [9–11].
While only 10–15% of women with ovarian cancer have
germline BRCA1 or BRCA2 mutations, recent data suggest that
sporadic ovarian cancers can harbor acquired genetic and
epigenetic defects in BRCA and in other DNA repair genes and
proteins, such as PTEN, RAD51, and Fanconi anemia (FA) genes
[7], that may contribute to the ‘‘BRCAness profile’’. Given the
shared role that BRCA1 and BRCA2 have with other DNA repair
genes, defects in these other DNA repair proteins alone could
influence response to treatment, recurrence rates, and overall
survival and increase sensitivity to PARP inhibitors. The challenge
is to define BRCAness profiles in sporadic ovarian cancer and
correlate this with clinical outcome.
Thus, the objective of this study is to define the BRCAness
profile of sporadic ovarian cancer. Specifically we aimed to
determine whether the expression of DNA repair proteins,
including PARP, FANCD2, BRCA1, PTEN, H2AX, ATM, as
well as p53, correlated with response to treatment, recurrence rate,
and survival in ovarian cancer.
Materials and Methods
Ethics Statement
All patients underwent ovarian cancer staging or debulking
surgery at the Roswell Park Cancer Institute in Buffalo, New York.
All pathology specimens were collected and reviewed in our
institution, and tumors were classified according to WHO criteria
[12]. The medical records of the patients were retrospectively
reviewed under an approved Roswell Park Cancer Institute
Institutional Review Board protocol that requires written patient
consent. The review included out- and inpatient treatment,
including surgery and chemotherapy. Overall survival and time
to progression were determined, each measured from the time of
diagnosis (at initial surgery). Progression was defined as objective
evidence of recurrence. The duration of overall survival was the
interval between diagnosis and death. Observation time was the
interval between diagnosis and last contact (death or last follow-
up). Data were censored at the last follow-up for patients with no
evidence of recurrence, progression, or death.
Antibodies
Six commercially available primary monoclonal antibodies were
used, specific for ATM (Abcam, Boston, MA), BRCA1 (Biocare
lab, Concord, CA), FANCD2 (Epitomics, San Francisco, CA),
PARP (Abcam), p53 (Novacastra, Lica Microsystems, Buffalo
Grove, IL), PTEN (Millipore, Billerica, MA), and a polyclonal
antibody to H2AX (Bethyl Laboratories, Montgomery, TX)
(Table 1). Detection was performed using the avidin-biotin-
peroxidase complex method (LASB-kit, Dakocytomation,
Glostrup, Denmark).
Tissue MicroArray Preparation
Paraffin-embedded tissues from 202 patients with ovarian
cancer were used to construct tissue microarrays as described
previously by Kononen et al. [13]. Briefly, after carefully choosing
the morphologically representative region from the hematoxylin-
eosin (HE) section, 0.6 mm cores were punched from the
individual paraffin-embedded blocks (donor blocks), and trans-
ferred to the receiver paraffin-embedded block (receiver block). To
overcome tumor heterogeneity, core biopsies were performed
from three different areas of each tumor. One section was stained
with H&E to confirm the presence of the tumor by light
microscopy.
Sections were incubated with antibodies to ATM, BRCA1,
FANCD2, PTEN, H2AX, PARP, and p53 (Table 1). The biotin-
free HRP enzyme-labeled polymer of the Envision Plus Detection
System (Dakocytomation) was used as a secondary reagent. The
diaminobenzidine complex was used as a chromogen. As a positive
control, endometrioid adenocarcinoma of the endometrium was
used for PTEN, ovarian serous carcinoma for p53, breast
carcinoma for PARP, ATM and BRCA1, normal tonsil for
FANCD2, and squamous cell carcinoma for H2AX. For negative
controls, a normal goat serum was used instead of the primary
antibody. The extent of immunochemical reactivity was graded
based on intensity as follows: 0 (background), 1+ (light), 2+
(moderate), 3+ (strong). Negative control slides omitting the
primary antibody were included in all assays.
Statistical Analyses
Statistical analyses were performed using SAS statistical
software (version 9.2; SAS Institute Inc, Cary, NC). The seven
DNA repair proteins (BRCAness profile) were measured at
baseline and were grouped as negative (no or light staining) and
positive (moderate or strong staining) based on staining intensity.
The associations between baseline cancer status (grade, stage,
histology type, and presence of residual tumor) and BRCAness
profile and the associations among p53, PARP, FANCD2 and
BRCA1 were examined using the Chi square and Cochran
Armitage trend tests.
Where possible, time from diagnosis to progression/recurrence
within the first 3 years was examined. Patients who died within 3
years were censored at the time of death, and patients who had
recurrence after 3 years or who did not have recurrence were also
censored at 3 years. The correlation of each protein staining
intensity and concurrence of multiple high levels of proteins with
3-year recurrence-free survival were evaluated using the Kaplan-
Meier (KM) method. Results from the KM method were then
verified by cumulative incidence rates with the event defined as
recurrence and the competing risk defined as non-recurrence
death using the cumulative incidence function [14]. Age and
cancer status adjusted hazard ratio of 3-year recurrence was
estimated using the Cox proportional hazard model. Association
between concurrence of multiple high levels of proteins and
recurrence status at 6 months and 1 year were also explored. All
reported p-values are two-sided, and a value of p,0.05 was
considered statistically significant.
Results
Patient characteristics at baseline are summarized in Table 2. A
total of 186 of 202 patients were studied. The mean age of the
study population was 62 years (range 33 to 89) and the median
duration of follow-up for recurrence was 22 months (range 20 days
to 3 years). As expected, the majority of the patients had poorly
differentiated, grade 3 cancers (161/186, 86.6%), stage III or IV
disease (174/186, 93.5%), and serous histology (164/186, 88.2%).
At surgery 59 patients had no residual disease while 125 patients
had at least minimal residual disease. All patients received
platinum-based first line chemotherapy. The median estimated
overall survival for all patients was 40.7 months (95% CI, 36.8–
45.0 months). The survivorship between patients with absence of
residual tumor (58.1%) and presence of residual tumor (59.7%)
were similar.
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cancer
The protein expression of ATM, FANCD2, PARP, PTEN,
H2AX, BRCA1 and p53 in epithelial ovarian tumor specimens was
investigated by immunocytochemistry and their associations with
ovarian cancer recurrence in 3 years are summarized in Table 3.
PARP was positive in 111 (60%) of the cases, FANCD2 was positive
in 68 cases (39%), H2AX was positive in 59% and p53 in 55% of the
cases. In contrast, most tumors were negative for BRCA1 (87%),
PTEN (in 89%) and ATM (92%). Although not statistically
significant, KM estimated 3-year recurrence-free survivals for
patients with high PARP (56.5% vs. 67.5%) and high FANCD2
(55.5%vs.66.9%)weremorethan10%lowerthantheirlowstaining
counterparts. Patients with high levels of PARP and/or FANCD2
were morelikely to also have high p53, 66% inboth positive, 53% in
either positive, and 43% in both negative were found have positive
p53 (p for trend=0.01, Figure 1). Overall, expression of either
FANCD2 or PARP was observed in 35% of the specimens. Co-
expression of PARP and FANCD2 was demonstrated in 56 of 173
(32%) specimens. High expression of PARP, FANCD2 and BRCA1
were significantly associated with each other, while no association
between BRCA1 and p53 was found (data not shown).
Correlation of FANCD2 and PARP Expression with Clinical
Outcome
Patients were divided into five mutually exclusive groups based
on their expression of PARP, FANCD2, and p53 (Figure 2).
Samples stained negative for all three proteins in 31 patients
(18%), positive for p53 alone in 51 patients (30%), and positive for
FANCD2 and PARP only in 19 patients (11%). Over 40% of
patients with positive PARP and/or FANCD2 had p53 protein
overexpression, including 37 (22%) with overexpression of all 3
proteins, and 32 (19%) with p53 and PARP or FANCD2
overexpression. KM estimated 3-year recurrence-free survival
curves for these mutually exclusive groups of p53, PARP and
FANCD2 are displayed in Figure 3, and the impact of the
BRCAness profile on recurrence-free survivorship is shown in
Table 4. Differences in survival of more than 10% at 12-months
and nearly 20% at 24-months was observed between the group
with positive staining for all three proteins (p53, PARP and
FANCD2) and the group with all three negative staining. The
survival trended toward being shorter in all three positive groups
compared to the other groups, although this was not statistically
significant in this small sample size (Figure 3A). We further
estimated 3 year recurrence-free survival curves between the
patients with high levels of all three proteins (p53, PARP,
FANCD2) and ‘‘other’’ patients as shown in Figure 3B. Patients
with all high levels were more likely to have earlier recurrence
within 3 years compared to all other patients (p=0.03). At 12
months after diagnosis, the recurrence-free survival was 81% for
patients with all positive levels of PARP, FANCD2 and p53 while
the remaining patients had a recurrence-free survival rate of
92%. At 18 months, the recurrence-free survival was 64% for the
group with all three positive proteins and 81% for all others, and
the cumulative recurrence incidence rate was 16.5% for patients
with all high levels of PARP, FANCD2 and p53 compared to
31.8% for the other patients. Patients with concomitant high
Table 1. Immunocytochemistry.
Antibody Product Cat. # Dilution Antigen retrieval Incubation
ATM Abcam Ab78 1/50 TRS 40 min steamer 1 hour
FANCD2 Epitomics S2909 1/100 Citrate buffer 20 min microwave 1 hour
HA2AX Bethyl Lab A300-082A 1/100 Citrate buffer 20 min microwave 1 hour
P53 Novacastra PA0057 1/50 Citrate buffer 20 min steamer 1 hour
PARP Abcam Ab110915 1/25 Citrate buffer 20 min steamer 1 hour
PTEN Millipore 04-035 1/100 Citrate buffer 20 min microwave 2 hours
BRCA1 Biocare CM345A,C 1/1000 Citrate buffer 20 min, room temperature Overnight
doi:10.1371/journal.pone.0030042.t001
Table 2. Patients’ Baseline Characteristics.
Characteristics Patients
No. (%)
No. Patients 186
Age (33 to 89 years old)
Mean 6 Std 62.0611.8
,50 30 (16.1)
50 to 59 50 (26.9)
60 to 79 51 (27.4)
.=70 55 (29.6)
Cancer status at diagnosis
Histology Type
Serous 164 (88.2)
Clear cell 10 (5.4)
Endometrioid 8 (4.3)
Mucinous 4 (2.1)
Stage
I 4 (2.2)
II 8 (4.3)
III 149 (80.1)
IV 25 (13.4)
Grade
1 7 (3.8)
2 18 (9.7)
3 161 (86.6)
Residual tumor at surgery
Absent 59 (32.1)
Present 125 (67.9)
doi:10.1371/journal.pone.0030042.t002
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P53 and BRCAness* 3-Year
Recurrence-Free Cumulative
Patients Survival Incidence P value
No. (%) % (Stderr) % (Stderr) (Logrank)
Overall 60.2 (0.04) 30.8 (0.04)
By group
PARP
Negative 74 (40.0) 67.5 (0.07) 24.7 (0.05) 0.14
Positive 111 (60.0) 56.5 (0.05) 36.2 (0.05)
FANCD2
Negative 105 (60.7) 66.9 (0.05) 27.5 (0.05) 0.15
Positive 68 (39.3) 55.5 (0.07) 35.8 (0.06)
H2Ax
Negative 70 (40.7) 59.0 (0.07) 30.9 (0.06) 0.76
Positive 102 (59.3) 64.2 (0.05) 30.8 (0.05)
PTEN
Negative 153 (88.9) 61.8 (0.05) 31.2 (0.04) 0.67
Positive 19 (11.1) 64.8 (0.06) 27.8 (0.11)
ATM
Negative 92 (53.8) 62.0 (0.06) 31.0 (0.05) 0.86
Positive 79 (46.2) 65.2 (0.06) 28.3 (0.05)
BRCA1
Negative 144 (86.7) 62.0 (0.05) 31.1 (0.04) 0.82
Positive 22 (13.3) 65.5 (0.12) 28.1 (0.10)
P53
Negative 81 (45.0) 64.9 (0.06) 27.4 (0.05) 0.54
Positive 99 (55.0) 58.1 (0.06) 34.7 (0.05)
Residual Tumor
Absent 59 (32.1) 58.1 (0.07) 37.6 (0.06) 0.61
Present 125 (67.9) 59.7 (0.05) 30.0 (0.04)
*Negative is defined as no or weak staining; positive is defined as moderate or strong staining.
doi:10.1371/journal.pone.0030042.t003
Figure 2. Distribution of five mutually exclusive groups of P53,
PARP and FANCD2. Distribution of five mutually exclusive groups of
P53, PARP, and FANCD2. 37 patients (22%) were positive for all three of
the proteins.
doi:10.1371/journal.pone.0030042.g002
Figure 1. Associations of PARP and/or FANCD2 with P53.
Association between PARP, FANCD2, and P53. Patients with positive
PARP or positive FANCD2 were more likely to have positive P53.
Patients positive for both PARP and FANCD2 were statistically more
likely to stain positive for P53.
doi:10.1371/journal.pone.0030042.g001
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recurrence within 3 years, after adjustment for age and cancer
status at the time of diagnosis (Table 4). The potential impact of
residual tumor and other baseline clinical factors on early
recurrence was accounted for using multivariate analysis.
Notably, the presence of residual tumor was not associated with
disease recurrence. However, patients with residual tumor after
initial surgery tended to have positive PARP, FANCD2, and P53
expression in comparison with the group with no residual tumor
(26% vs 14%, P=0.07).
In this study, we defined platinum resistant disease as disease
recurring within 12 months of primary treatment completion,
while recognizing that the more standard definition would mark
platinum resistance as recurrence after 6 months. Therefore,
Figure 4 explores the concurrent expression of PARP, FANCD2
and P53 in patients with and without 6-month and 12-month
recurrence. Among the 4 patients who had recurrence within 6
months, 2 (50%) had all 3 positive, while 34 of 162 (21%) without
recurrence had all 3 positive levels. Among the 17 patients who
recurred within the first year of diagnosis, approximately 41% (7/
17) had tumors with high levels of all 3 proteins, compared to 19%
(29/149) with all 3 positive in no recurrence group (P=0.04).
Therefore, early recurrence, which is representative of platinum
resistant disease, seems to be marked by concomitant high levels of
PARP, FANCD2 and p53.
Figure 3. Kaplan-Meier Estimated 3-Year Recurrence-Free Survival
Curves. Kaplan-Meier estimated 3-year recurrence-free survival curves. A:
No difference in recurrence-free survival when each of the 5 mutually
exclusive groups by expression of PARP, FANCD2, and P53 were examined
independently. B: Patients positive for all three PARP, FANCD2, and P53 had
lower recurrence-freesurvival compared topatients not positivefor all three.
doi:10.1371/journal.pone.0030042.g003
Table 4. High Levels of PARP, FANCD2 and P53 on Risk of 3-Year Recurrence.
KM Recurrence-Free Survival (%)/ Cox Proportional Hazard
Group Patients Cumulative Incidence (%) Unadjusted Adjusted*
No. (%) 6-mo 12-mo 18-mo 24-mo HR (95% CI) HR (95% CI)
Other 133 (78.2) 99.2/0.8 92.1/7.1 80.8/16.5 70.4/24.5 1 1
All Three Positive 37 (21.8) 97.0/2.9 81.1/17.1 63.8/31.8 55.8/37.8 1.92 (1.05, 3.54) 1.88 (1.02, 3.49)
*Adjusted for age, cancer status (grade, histology type and stage) at diagnosis and the presence of residual tumor at surgery.
doi:10.1371/journal.pone.0030042.t004
Figure 4. Association between Early Recurrence and Positive
P53, PARP, and FANCD2. Association between positive P53, PARP,
and FANCD2 in patients with and without early recurrence. Patients
with early recurrence at both 6 and 12 months after diagnosis were
much more likely to have high levels of all 3 proteins (50% at 6 months
and 41.2% at 12 months).
doi:10.1371/journal.pone.0030042.g004
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Recently, the role of DNA repair genes and proteins in ovarian
cancer, the concept of BRCAness of ovarian cancers, as well as
the mechanism of synthetic lethality has emerged as essential for
the understanding of ovarian cancer pathogenesis and pathways
to new treatments [7,8]. As 20% of high grade serous sporadic
ovarian carcinomas have BRCA1 and BRCA2 mutations, the
role of HR in ovarian cancer has been well established [15,16].
However, many hereditary and sporadic ovarian cancers do not
possess BRCA mutations or altered BRCA expression and thus
we reasoned that loss of other HR proteins may contribute to
ovarian cancer. In fact, epigenetic silencing of FANCF via
promoter methylation [17] and reduced levels of FANCD2 [18]
have been previously detected in ovarian cancer. We further
reasoned that overexpression of different HR proteins may
account for acquired platinum-resistance and therefore can be
used as a potential screen to (i) identify patients at a higher risk
for recurrence and (ii) identify new therapeutic targets. To
measure the BRCAness (i.e. the HR) profile of sporadic ovarian
cancers, we used immunocytochemistry (ICH) to examine protein
expression of DNA damage response proteins FANCD2,
BRCA1, PARP, H2AX, and ATM, as well as PTEN and p53,
tumor suppressor genes that also have a function in maintaining
genomic stability by engaging in DNA repair [19–25] in a panel
of sporadic ovarian carcinomas.
To our knowledge, there has been no previous systematic
analysis of ATM and H2AX expression in ovarian cancers. Here
we found that the proteins were expressed in 46% and 59% of our
samples respectively, which may indicate their potentially
compensatory expression in HR deficient cells.
Supporting the role of p53 and PTEN as tumor suppressors, the
majority of ovarian carcinomas tested was positive for p53 (55%),
as the antibody detects both wildtype and mutated forms of p53,
and negative for PTEN expression (89%). These results are similar
to other studies with advanced cancers [21–22].
Interestingly, we found that 86.7% of the cases had negative
BRCA1 ICH. Most of the prior studies on BRCA1 deficiency in
sporadic ovarian cancer have focused on mutational analysis,
methylation studies, and gene expression, with only a few
immunocytochemical studies. A recent report by Skytte et al.
revealed negative BRCA ICH in only 20% of ovarian cancers
[26]. These differences may be explained by the use of different
antibodies to detect the BRCA protein [27]. In fact, in a
comparative study of 84 cases with sporadic breast cancer with
four different anti-BRCA antibodies, Al-Mulla et al. detected
BRCA1 protein expression loss in 83% of the cases using the
same BRCA antibody AB-1, against the N-terminus epitope [28].
In the NCIC study which correlated BRCA1 protein expression
by ICH with corresponding clinical data, 251 ovarian cancer
samples were analyzed using a mouse monoclonal BRCA1
antibody (MS110, Calbiochem, Germany) and 65% of the
tumors showed no staining or very mild staining [29]. The
antibody used in our study was different from the antibodies used
in the prior studies. In addition, because of the small sample size
in our study and similarly in the NCIC study, our scoring
grouped the staining results of four categories to negative (no or
weak) and positive (moderate or strong) based on staining
intensity. It therefore remains necessary for future studies to
clearly outline the guidelines for BRCA1 staining and scoring in
studies of this marker. Nevertheless, the loss of BRCA1 in the
majority of tumors in our study coupled with the increased
expression of PARP in most of the cancers (discussed below)
suggests that PARP upregulation may be a compensatory
mechanism by cancer cells to withstand platinum-therapy-
induced death.
Our results with PARP are also consistent with previous studies.
We found high expression of PARP in 60% of specimens, similar
to prior reports suggesting positive PARP protein staining in 76%
of ovarian carcinomas [26]. Moderate FANCD2 staining was
found in most (85%) stage I serous carcinomas of the ovary
[Pejovic, unpublished data], while in this series we find that 40%
of advanced serous carcinomas overexpress FANCD2. Thus,
overexpression of FANCD2 in addition to PARP may increase the
capacity of cells to repair DNA double- and single-strand breaks
contributing to platinum resistance.
Synergy among PARP, FANCD2 and p53 protein expression is
one of the striking results in our study. Tumors with high
expression of PARP and/or FANCD2 were more likely to show
overexpression of p53. The protein profile defined by high
expression of all three proteins PARP, FANCD2, and p53 is
associated with a high risk of recurrence. Not only was recurrence
rate at three years twice as high in this group, but it is particularly
noteworthy that over half of patients recurring within the first 12
months after primary treatment (platinum resistant disease) had
significantly elevated expression of these three proteins. This
subgroup of patients with particularly difficult to treat ovarian
cancer has not been previously identified by protein or other
molecular profiling. Thus, these results allow both identification of
women at higher risk for relapse and suggest potential therapeutic
targets. Recently, promising results were reported in a phase II
clinical trial of PARP inhibitor BSI-201 (iniparib) in combination
with gemcitabine and carboplatin in 19 patients with platinum
resistant ovarian cancer [30].
Our study has several limitations. First, though we examined
186 patients, this is still a limited sample size for all clinical
correlations examined. Second, patients who are BRCA1 and
BRCA2 mutation carriers have not been identified in this study.
The strict guidelines for prognostic studies using immunocyto-
chemistry using standardized criteria are still being developed.
Also we examined only a subset of DNA repair proteins, while
inclusion of other proteins involved in the HR such as ATR,
CHK2 or RAD51, and functional studies of RAD51 foci
formation to evaluate the sensitivity of these cells to PARP (and
FANCD2) inhibition are currently underway.
Finally, while we believe that the most important results of this
study are (i) identification of a BRCAness profile that is not
associated with BRCA1 and (ii) association of this triple-positive
ovarian cancer (FANCD2+/PARP+/P53+) with very early
recurrence of ovarian cancer and therefore platinum resistance.
These patients may benefit from dual inhibition of FANCD2 and
PARP and/or small molecules targeting mutated p53. In fact,
inhibition of the FA/BRCA pathway in sporadic cancers by
different compounds including circumin, has been shown to
sensitize cancers to platinum agents [31]. Thus, combined
treatment of FA/BRCA pathway inhibitors and PARP inhibitors
already in clinical trials may be an effective treatment for relapsed
patients that have been identified to overexpress FANCD2 and
PARP.
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